Zimmer boosts biologics with ETEX buy
This article was originally published in Clinica
Orthopedic firm Zimmer has bolstered its biologics portfolio by acquiring ETEX Holdings for an undisclosed fee. The Cambridge, Massachusetts firm has several bone void filler products including the injectable Beta-bsm, Gamma-bsm putty, CarriGen and EquivaBone. Zimmer’s existing biologics offering includes Gel-One, an injectable hyaluronate gel approved for the treatment of osteoarthritis of the knee; Chondrofix, an osteochondral allograft for osteochondral lesions in the ankle; and the Denovo NT juvenile cartilage implant for the repair of articular cartilage damage. “ETEX's innovative bone substitute material products add more depth to a growing portfolio of solutions for the early stages of joint disease," stated Joseph Cucolo, president of Zimmer Americas. The purchase is Zimmer’s second this year: in April, it splashed out $13.35bn on Biomet, propelling it to the number-two position in the overall orthopedic market.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.